TUCSON, Ariz., March 07, 2017 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM ), a provider of instruments, reagents and services for molecular profiling applications, today announced that Ann F. Hanham, Ph.D., a director since August 2016, has been appointed to the Chair of the company’s board of directors.
“We are delighted and honored to welcome Dr. Hanham to this new role on our board of directors,” said TJ Johnson, CEO of HTG. “Her executive experience in the biotech and investment industries, scientific knowledge and full understanding of board service and leadership make her ideally suited to help HTG navigate the next stages of its growth.”
Dr. Hanham has served for more than 15 years in the life science investment industry as a founding member and managing partner of BAR Capital Management, LLC, and, prior to that, as a managing director and general partner of Burrill & Company. Earlier in her career, Dr. Hanham held positions of increasing responsibility in clinical and regulatory affairs and product development at various companies including InterMune Inc., Otsuka America Pharmaceuticals, Inc., Celtrix Pharmaceuticals, Inc., and Becton Dickinson and Company. She currently serves as a director for two other public companies, and has served on the boards of directors of over 20 companies, both private and public, throughout her distinguished career.
“During my time with HTG’s board of directors I have gained a strong appreciation of the company’s technology, capabilities and position in the molecular profiling market, and the important solutions the company makes available for its customers,” stated Dr. Hanham. "I look forward to continuing to work with the board and management, in this new role, to help HTG realize its potential,” she continued.
About HTG:
Headquartered in Tucson, Arizona, the mission of HTG Molecular Diagnostics (HTG) is to empower precision medicine at the local level. In 2013 the company commercialized its first instrument platform and a portfolio of RNA assays that leveraged HTG's original proprietary nuclease protection chemistry. Continuous improvement led to the 2014 launch of the company’s HTG EdgeSeq product line, which automates sample and targeted library preparation for next-generation sequencing. Additional information is available at www.htgmolecular.com .
Safe Harbor Statement:
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about our newly appointed board chairwoman and her expected benefits to us, the potential of our technology and product and service solutions, and our market position and the capabilities of our technology. Words such as "believes," "anticipates," "plans," "expects," "intends," "will," "goal," "potential" and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements necessarily contain these identifying words. These forward-looking statements are based upon management's current expectations, are subject to known and unknown risks, and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, including, without limitation, risks associated with the process of developing and commercializing new and current products, our ability to achieve and sustain sufficient market acceptance, and the capabilities of our product and service solutions to keep pace with rapidly changing technology and customer requirements. These and other factors are described in greater detail in our filings with the Securities and Exchange Commission, including without limitation our Quarterly Report on Form 10-Q for the Quarter ended September 30, 2016. All forward-looking statements contained in this press release speak only as of the date on which they were made, and we undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
Contact: Westwicke Partners Jamar Ismail Phone: 415-513-1282 Email: jamar.ismail@westwicke.com TJ Johnson President / CEO HTG Molecular Diagnostics Phone: 520-547-2827 x130 Email: tjjohnson@htgmolecular.com
